Alnylam initiates Stage II study with ALN-TTRsc for treatment of ATTR Alnylam Pharmaceuticals.

Individuals completing the Stage II trial will be eligible to participate in an open-label extension study for additional evaluation of general tolerability and medical activity with long-term dosing; the ALN-TTRsc Stage II OLE study is expected to end up being initiated in mid-2014. Alnylam reported positive results from a Stage We trial with ALN-TTRsc in 28 healthy volunteers in the centre Failure Culture of America 17th Annual Scientific Conference held in September 2013. The total results of the medical study showed that ALN-TTRsc administration led to robust, constant, and statistically significant knockdown of serum TTR as high as 94 percent.By inhibiting PD-L1, atezolizumab might enable the activation of T cells, restoring their ability to detect and attack tumor cells effectively. A strategic study collaboration and license agreement to develop and commercialize the next era of novel Chimeric Antigen Receptor T cell immunotherapies with Kite Pharma. About Amgen Amgen is focused on unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This process begins by using tools like advanced human being genetics to unravel the complexities of disease and understand the fundamentals of human being biology.

Other entries from category "immunology":

Random entries